- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07693595
Nailfold Capillaroscopic Changes in Psoriasis
July 4, 2026 updated by: Hadil Jamil Matar Albarrawi, Al-Azhar University
Nailfold Capillaroscopic Changes in Psoriasis and Its Correlation With Disease Severity
The goal of this observational study is to evaluate nailfold capillaroscopic changes in patients with psoriasis and to assess their correlation with disease severity.
The study will also explore differences in capillaroscopic findings across different clinical types of psoriasis and skin phototypes (Fitzpatrick classification).
The study will include patients diagnosed with psoriasis attending dermatology outpatient clinics.
Participants will undergo clinical assessment and nailfold capillaroscopy to detect microvascular changes.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ahmed H Nouh, Asst Prof Derm & Venereol
- Phone Number: +201062034079
- Email: Dr.ahmednouh@azhar.edu.eg
Study Contact Backup
- Name: Hadil J Albarrawi
- Phone Number: +201096205545
- Email: hadeeljamil71@gmail.com
Study Locations
-
-
-
Cairo, Egypt
- Al-Hussein University Hospital & Sayed Galal University Hospital
-
Contact:
- Ahmed H Nouh, Asst Prof Derm & Venereolog
- Phone Number: +201062034079
- Email: Dr.ahmednouh@azhar.edu.eg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The study will include patients clinically diagnosed with psoriasis attending the dermatology outpatient clinics at Al-Hussein and Sayed Galal University Hospitals in Cairo, Egypt during the study period.
Description
Inclusion Criteria:
- Patients clinically diagnosed with psoriasis.
Exclusion Criteria:
- Patients with connective tissue diseases (e.g., systemic sclerosis, SLE)
- Diabetes mellitus or peripheral vascular disease
- Current smokers
- Pregnant or lactating women
- Recent use of vasodilators or beta-blockers
- Manual workers exposed to vibrating tools
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nailfold capillaroscopic abnormalities in psoriasis patients
Time Frame: Baseline
|
Detection and description of nailfold capillaroscopic (NFC) abnormalities in patients with psoriasis.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variation of nailfold capillaroscopic findings among different clinical types of psoriasis and correlation with disease severity (PASI score).
Time Frame: Baseline
|
Correlation between PASI score and presence of NFC changes. - Comparison of nailfold capillaroscopic findings in different types of psoriasis |
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
May 1, 2027
Study Registration Dates
First Submitted
July 4, 2026
First Submitted That Met QC Criteria
July 4, 2026
First Posted (Actual)
July 9, 2026
Study Record Updates
Last Update Posted (Actual)
July 9, 2026
Last Update Submitted That Met QC Criteria
July 4, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PSO-NFC-PASI-2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeWithdrawnPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allActive, not recruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Alumis IncActive, not recruitingPsoriasis | Plaque Psoriasis | Psoriasis (PsO) | Moderate Psoriasis | Severe PsoriasisUnited States, Canada, Australia, Germany, Spain, Hungary, Japan, Bulgaria, Poland, Czechia, Estonia, Latvia, Puerto Rico, Portugal, South Korea, France
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Caja Costarricense de Seguro SocialNot yet recruitingPsoriasis | Psoriasis (PsO) | Psoriasis Arthritis | Psoriasis PatientsCosta Rica
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaActive, not recruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.Active, not recruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
Clinical Trials on Nailfold Capillaroscopy
-
ASST Gaetano Pini-CTOEULAR study group on microcirculation in rheumatic diseasesCompleted
-
Mayo ClinicEnrolling by invitationGastric Antral Vascular EctasiaUnited States
-
University of ManchesterNorthern Care Alliance NHS Foundation Trust; Royal Free Hospital NHS Foundation... and other collaboratorsCompletedSystemic Sclerosis | Raynaud PhenomenonUnited Kingdom
-
Assiut UniversityNot yet recruitingSystem Lupus Erythematosus
-
China Medical University HospitalUnknown
-
John Hunter HospitalCompletedType 1 Diabetes MellitusAustralia
-
University of Erlangen-Nürnberg Medical SchoolRecruitingCOVID-19 | Long COVID | COVID-19 Respiratory InfectionGermany
-
Muğla Sıtkı Koçman UniversityCompletedChronic Kidney Disease | Geriatrics | Carotis Intima-media ThicknessTurkey (Türkiye)
-
Icahn School of Medicine at Mount SinaiCompleted
-
CHU de Quebec-Universite LavalRecruitingUndifferentiated Connective Tissue DiseasesCanada